Alumis Inc. (ALMS)
Last updated: 2026-10-22 05:33:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Summary
Alumis Inc. (ALMS) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $6.81, with a market capitalization of $820.62M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $4.37 to $31.35. This page covers its latest market performance, valuation, price trends and company information.
Key Market Data
$820.62M | |
$6.75 | |
$31.35 | |
$2.76 | |
$6.70 | |
1.00M | |
2.57M | |
-- | |
$31.35 | |
$4.37 | |
-- | |
-- |
Alumis Inc. (ALMS) Latest Closing Stock Price
Alumis Inc. (ALMS) last closed at $6.70 as of 2026-10-21 23:31:00, unchanged from the previous close of $6.70.
During the latest regular trading session, ALMS traded between $2.76 and $31.35, with a volume of 1.00M shares. The closing price was near the lower end and near the lower end of its 52-week range.
Alumis Inc. (ALMS) 7-Day Stock Price Change
Over the past seven days, Alumis Inc. (ALMS) moved from $7.06 to $6.81, representing a decline of 3.51% ($0.25).
The stock traded between $6.01 and $7.31 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 2.01 million shares, down versus the previous seven-day period, indicating lower trading activity.
ALMS 52-Week Price Position
Position in Range: 9.1%
ALMS is currently trading at $6.81, placing it 9.1% of the way from its 52-week low of $4.37 to its 52-week high of $31.35. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
What is Alumis Inc. (ALMS)?
Alumis Inc is a clinical-stage biopharmaceutical company with an initial focus on developing its two Tyrosine Kinase 2 ("TYK2") inhibitors: envudeucitinib ("envu"), an allosteric TYK2 inhibitor for the treatment of PsO and SLE; and A-005, a central nervous system ("CNS") penetrant allosteric TYK2 inhibitor, to offer the therapeutic benefit of TYK2 inhibition within the CNS for a broad range of neuroinflammatory and neurodegenerative diseases.
Alumis Inc. Information
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 239 |
| Exchange | NASDAQ |
| Company Website |
How to Buy Alumis Inc. (ALMS) Stock on MEXC
Eligible investors can buy real shares of Alumis Inc. (ALMS) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Frequently Asked Questions (FAQ)
1.What is Alumis Inc. (ALMS) stock price today?
2.Is ALMS stock going up or down today?
3.What is ALMS pre-market price?
4.What is ALMS after-hours price?
5.Is ALMS stock trading now?
6.Where does ALMS sit relative to its 52-week high and low?
7.What sector is Alumis Inc. in?
8.What is Alumis Inc.'s market capitalization and where is it listed?
9.How is ALMS valued in terms of P/E ratio and EPS?
10.Does Alumis Inc. pay a dividend?
Explore More US Stocks
Search Stocks
ALMS Stock Calculator
Estimate the value between ALMS shares and USD.
ALMS Shares to USD
1.00 ALMS shares = 6.812 USD
Calculations are estimates based on the latest available price and are for reference only.


